Prof. Dr. Heiko Lickert

At the Institute of Diabetes and Regeneration Research, Heiko Lickert and his team study the development and regeneration of the pancreas, and in particular of the insulin-producing β-cells, and how we can use this knowledge to find a cure for diabetes. His research includes in-depth basic research to achieve a better understanding of how β-cells form during development and how they lose function or get lost during diabetes progression. The main goal is to develop novel regenerative therapeutic approaches for the treatment of diabetes mellitus in order to go beyond current symptomatic treatment and stop the progression of the disease. Findings from his studies serve as a solid basis to either regenerate β-cells directly in the patient (β-cell regeneration therapy) or replace lost β-cells with stem cell-generated β-cells (β-cell replacement therapy).

Heiko Lickert is a leading expert in the field of developmental, stem cell, and islet biology. Since 2011 he is the Director of the Institute of Diabetes and Regeneration Research at the Helmholtz Munich and  W3 Professor and Chair of Beta Cell Biology in the Medical Faculty of the Technical University Munich. Heiko started his scientific career at the Albert-Ludwigs University and Max-Planck Institute in Freiburg, where he received his PhD with distinction in the field of molecular embryology. He then moved for his postdoctoral studies to the Mount Sinai Hospital in Toronto, where he gained experience in the field of endoderm development and organogenesis. In 2005, he transferred his research to Helmholtz Munich where he worked on endoderm, pancreas, and endocrine lineage development, homeostasis, and regeneration as an Emmy-Noether junior group leader funded by the German Research Foundation.

He is the recipient of several prestigious prizes like the Werner-Creutzfeldt-Preis from the Deutsche Diabetes Gesellschaft (DDG - 2020), the PRO-SCIENTIA-Förderpreis from the Eckhart-Buddecke-Stiftung (2020), the Paula and Richard von Hertwig Award for Interdisciplinary Cooperation from Helmholtz Munich (2018 and 2011), the Otto-Hahn Medal from the Max-Planck Society (2003), and the Hans-Spemann Award from the Albert-Ludwigs University in Freiburg (2002).

His work is funded by the European Research Council (ERC Starting and Advanced grant), Breakthrough Type 1 Diabetes, Bavarian State  (m4 Award), European Commission (consortium ISLET), Federal Ministry of Research, Technology and Space  (BeISLET consortium),  German Research Foundation (DFG), Novo Nordisk and Eli Lilly for an industry partnership, Helmholtz-Gemeinschaft (HGF) and the German Center for Diabetes Research (DZD).

He is involved in several institutional responsibilities:

•    President of the German Stem Cell Network 2025/2026

•    Member of the Academia Europaea (since 2024)
•    Honorary Fellow and member of the Institute of Advanced Study of the TUM (since 2022)
•    Board of Directors of the International Society of Differentiation (since 2018)
•    Advisory Board and Graduate School Steering Committee – TUM, Medical Faculty (2017-2025)
•    Member of the Research Coordination Board and of the Advisory Board of the German Center for Diabetes Research (DZD) (since 2016)
•    Member of the Steering Committee of the Helmholtz Diabetes Center (HDC) (since 2016)